Centrum Badawczo – Rozwojowe Novasome sp. z o.o. and Pikralida sp. z o.o. are collaborating on the research project titled Development of an innovative pilot line and its validation under real conditions using synthesis process of a model active pharmaceutical ingredient.
The project POIR.01.01.01-00-0072/21 is co-financed by the European Funds.
The aim of the Project is to develop a technology innovation and to verify the latter in real conditions using a pilot kilo-lab line that enables efficient and safe synthesis of active pharmaceutical ingredients (APIs). The Project will involve the design of a process system to allow for a variety of synthesis processes as well as the on-line monitoring of how individual reactions proceed. Once implemented, the innovation will contribute to the integrity of supply chains and availability of APIs, and therefore to ensuring pharmaceutical sovereignty in the EU.
- Total Project Budget: 9 582 401,43 PLN
- Funding from European Funds: 5 765 803,30 PLN
- Project Period: 01.07.2021 – 31.12.2023
The project is co-financed by the European Union under the Smart Growth Operational Program 2014-2020. The program is implemented as part of the call organized by the National Centre for Research and Development 1/1.1.1/2021 Fast Track.
Co-funded projects:
Project no. POIR.01.01.01-00-0235/20
Utilisation of a matrix metalloprotease inhibitor to develop an innovative therapeutic method that prevents the development of post-traumatic and post-stroke epilepsy.
Project no. POIR.04.01.04-00-0063/20-00
Development of the innovative formulation of the combination drug dedicated for the geriatric patients in pain pharmacotherapy
Project no. TANGO-IV-C/0012/2019
Development of an innovative combined preparation dedicated for the treatment of hypertension.
Project no. RPWP.01.02.00-30-0047/19-00
Establishment of a R&D Laboratory of Super Generic Drugs.